Company / Free Cash Flow
ADMA Biologics, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$27.8M
FY2025
5-year range
-$125.9M / $110.4M
FY2021-FY2025
Trend
-74.8%
vs FY2024
Sector context
#61 of 194
Health Care
What the data says
At $28M, ADMA Biologics, Inc.'s free cash flow ranks #61 of 194 in the Health Care sector. Improved from $4M to $28M over the past 2 years.
Based on SEC 10-K filings.
$28M in FY2025.
Improved from $4M to $28M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#61 of 194 in Health CareTop 31% of 194This company $27.8M Sector average $470.8M
▼
-94.1% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 74.8% year-over-year.
- Ranks #61 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2024.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.8M | -74.8% |
| FY2024 | $110.4M | +2641.3% |
| FY2023 | $4.0M | +103.2% |
| FY2022 | -$125.9M | -0.0% |
| FY2021 | -$125.9M | -9.7% |
| FY2020 | -$114.7M | -43.4% |
| FY2019 | -$80.0M | -23.5% |
| FY2018 | -$64.8M | -253.1% |
| FY2017 | -$18.3M | +0.0% |
| FY2016 | -$18.3M | -7.7% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026